Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/15/16
End: 06/01/21
Due: 06/01/22
Phase: N/A
Priority: Normal
Start: 12/02/15
End: 12/31/21
Due: 12/31/22
Phase: N/A
Priority: Normal
Start: 05/27/19
End: 12/31/22
Due: 12/31/23
Phase: N/A
Priority: Normal
Start: 05/01/16
End: 06/01/21
Due: 06/01/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies | NCT03366350 | Wuhan Sian Medical Technology Co., Ltd | user2@example.com | None | 2016-04-15 | 2021-06-01 | 2022-06-01 | - | - | 2025-07-14 |
| CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | NCT02965092 | Wuhan Sian Medical Technology Co., Ltd | user2@example.com | None | 2015-12-02 | 2021-12-31 | 2022-12-31 | - | - | 2025-07-14 |
| Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | NCT04008251 | Wuhan Sian Medical Technology Co., Ltd | user2@example.com | None | 2019-05-27 | 2022-12-31 | 2023-12-31 | - | - | 2025-07-14 |
| Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies | NCT03366324 | Wuhan Sian Medical Technology Co., Ltd | user2@example.com | None | 2016-05-01 | 2021-06-01 | 2022-06-01 | - | - | 2025-07-14 |